The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Statement regarding Finance Director Steve Fenerty

14 Feb 2018 16:35

RNS Number : 9206E
H&T Group PLC
14 February 2018
 

14th February 2018

 

 

H&T Group plc

("H&T" or "the Group" or "the Company")

 

Statement regarding Finance Director, Steve Fenerty

 

 

The Board of H&T Plc announces that its Finance Director, Steve Fenerty, has recently been diagnosed with leukaemia. He is receiving first class treatment and remains actively involved with the running of the business.

 

Peter McNamara, Chairman said, "We have a clear strategy headed by CEO John Nichols. Steve Fenerty is well supported by Tatiana Hagan, part of a first class finance team he has developed over recent years. Steve Fenerty will have further assistance given by an interim appointment from an experienced Financial Officer from within the sector. 

 

We all wish Steve well in his treatment and recovery."

 

 

- ENDS -

 

 

 

Enquiries:

 

H&T Group plc

Tel: 0870 9022 600

John Nichols, chief executive

Steve Fenerty, finance director

 

Numis Securities (broker and nominated adviser)

Tel: 020 7260 1000

Mark Lander, corporate broking

Freddie Barnfield, nominated adviser

 

Haggie Partners (public relations)

Tel: 020 7562 4444

Damian Beeley

Brian Norris

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRSFEFMLFASEEE

Related Shares

Back to RNS

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.